Intensive treatment in order to minimize the Ph-positive clone in CML. Danish-Swedish CML Group.
With the rationale that a significant reduction of the malignant clone in CML might prolong time to metamorphosis, intensive treatment was given to patients < or = 55 years. Six months of hydroxyurea and high dose interferon-alpha (IFN-alpha) was followed by one to three courses of intensive chemotherapy. Patients who had a donor were allotransplanted and patients who became Ph-negative in bone marrow were autotransplanted. On 1 May 1995, 160 patients were registered in the study. Fifty-one percent of the patients who received six months IFN-alpha and hydroxyurea had a significant Ph-reduction and 5% became Ph-negative. The corresponding figures after two intensive chemotherapy courses were 47 and 28%, respectively. Twenty-seven of 30 autotransplanted patients have been analysed for Ph. Seventeen have relapsed cytogenetically, while ten are Ph-negative 1-64 + months after ABMT. BMT was performed in 59 patients. The actuarial 6-year survival from diagnosis of all 160 registered patients is 68%, which seems to be better than for age-matched historical controls.
Simonsson
B
B
Department of Medicine, University Hospital, Uppsala, Sweden.
Oberg
G
G
Björeman
M
M
Björkholm
M
M
Carneskog
J
J
Gahrton
G
G
Hast
R
R
Karl
H
H
Lanng-Nielsen
J
J
Löfvenberg
E
E
Malm
C
C
Turesson
I
I
Udén
A M
AM
Vilén
L
L
Weis-Bjerrum
O
O
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003718:Denmark; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D013548:Sweden; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D016898:Interferon-alpha; D006918:Hydroxyurea